Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neurotrope Inc.

Developing Alzheimer's diagnostic, treatment

This article was originally published in Start Up

Executive Summary

Theories regarding the basis of Alzheimer’s disease have focused primarily on beta-amyloid and tau proteins, but still today no one can say for certain whether these proteins are causative, or merely symptomatic of some other disease process. Neurotrope Inc. is pursuing a new suspect, protein kinase C-epsilon, based on observations that a shortage of PKCe in the brain correlates with erosion of synapses that prevents neurons from functioning properly, and thus leads to loss of neural and motor skills.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts